期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性粒细胞白血病对伊马替尼的耐药机制研究进展 被引量：4

Progress in Research on the Resistance of Chronic Myeloid Leukemia Cells to Imatinib
下载PDF
导出
摘要 慢性粒细胞白血病（chronic myeloid leukemia,CML）是一种造血干细胞克隆增殖性疾病。95%以上的CML患者可检测到特征性的费城（Ph）染色体和bcr-abl融合基因。该融合基因编码一种具有酪氨酸激酶活性的蛋白,通过一系列复杂的细胞信号转导途径,使造血干细胞发生异常转化而导致CML的发生[1]。伊马替尼是治疗CML的一线药物。
作者 苗圣超 糜坚青
机构地区 上海交通大学医学院附属瑞金医院血液科
出处 《中国临床医学》 2014年第6期740-744,共5页 Chinese Journal of Clinical Medicine
基金 973国家重点基础研究发展计划(编号:2010CB529203) 上海市慈善癌症研究中心慈善慢跑课题
关键词 伊马替尼 耐药机制研究 融合基因 克隆增殖性疾病 造血干细胞 移码突变 细胞信号转导 MYELOID 点突变 耐药程度
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献62

  • 1Goldman JM.Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment[J].N Engl J Med , 2003.349(15),1451-1464.
  • 2Faderl S. Talpaz M. Estrov Z. et al. The biology of chronic myeloid leukemia[J]. N Engl J Med.1999.341(3) :164-172.
  • 3Fader! S. Hochhaus A. Hughes T. Monitoring of minimal residual disease in chronic myeloid leukemia[J]. Hematol Oncol Clin North Am.2004. 180) ,657-670. ix-x,.
  • 4Alvarez Rl-l s Kantarjian HvCortes JE. The biology of chronic myelogenous leukemia, implications for imatinib therapy[J]. Semin Hematol.2007.44(1 Suppl 1) ,54-S14.
  • 5Druker BJ. Talpaz M.Resta OJ .et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med. 2001,344 (14) : 1031- 1037.
  • 6Cohen MH, Williams G.Johnson JR.et al. Approval summary for imatinib mesy!ate capsules in the treatment of chronic myelogenous leukemia[J]. Clin Cancer Res.2002.8(5) :935-942.
  • 70' Brien SG. Guilhot F. Larson RA. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J]. N Eng! J Med, 2003.348(11).994-1004.
  • 8Hughes TP. Kaeda J. Branford S. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia[J]. N Engl J Med.2003 .349(15) .1423-1432.
  • 9Apperley JF. Part I. mechanisms of resistance to imatinib in chronic myeloid leukaemia [J]. Lancet Oncol , 2007.8 (11) : 1018-1029.
  • 10Branford S.Rudzki Z. Walsh Sv et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance. and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis[J]. Blood.2003,102(1) .276-283.

同被引文献36

  • 1江倩.初发慢性髓性白血病慢性期诊断与一线治疗[J].中国实用内科杂志,2013,33(7):536-539. 被引量：4
  • 2AlmeidaMH,FogliattoL,CoutoD.ImportanceofadherencetoBCR-ABLtyrosine-kinaseinhibitorsinthetreatmentofchronicmyeloidleukemia[J].RevistaBrasileiradeHematologiaeHemot-erapia,2014,36(1):54-59.
  • 3DrukerBJ,O’BrienSG,GuilhotF,etal.Five-yearfollow-upofpatientsreceivingimatinibforchronicmyeloidLeukemia[J].NEnglJMed,2006,355(23):2408-2417.
  • 4CastagnettiF,TestoniN,LuattiS,etal.Deletionsofthederivativechromosome9donotinfluencetheresponseandtheoutcomeofchronicmyeloidleukemiainearlychronicphasetreatedwithima-tinibmesylate:GIMEMACMLworkingpartyanalysis[J].JClinOncol,2010,28(16):2748-2754.
  • 5SteinB,SmithBD.Treatmentoptionsforpatientswithchronicmy-eloidleukemiawhoareresistanttoorunabletotolerateimatinib[J].ClinicalTherapeutics,2010,32(5):804-820.
  • 6HardanI,StanevskyA,VolchekY,etal.TreatmentwithInterferonalphapriortodiscontinuationofImatinibinpatientswithchronicmyeloidleukemia[J].Cytokine,2012,57(2):290-293.
  • 7BrecciaM,AlimenaG.Thesignificanceofearly,majorandstablemolecularresponsesinchronicmyeloidleukemiaintheimatinibera[J].CriticalReviewsinOncology/Hematology,2011,79(2):135-143.
  • 8YilmazM,KantarjianH,JabbourE,etal.SimilarOutcomeofPa-tientsWithChronicMyeloidLeukemiaTreatedWithImatinibinorOutofClinicalTrials[J].ClinicalLymphomaMyelomaandLeu-kemia,2013,13(6):693-699.
  • 9JoergH,MicheleB,VerenaH,etal.Predictingcompletecytoge-neticresponseandsubsequentprogression-freesurvivalin2060patientswithCMLonimatinibtreatment:theEUTOSscore[J].Blood,2011,118(3):686-692.
  • 10StagnoF,VigneriP,RaimondoFD.Towardsaneedtoa“biologicalSokalrisk”intheeraoftyrosinekinaseinhibitorsinchoosingfront-linetherapyinchronicmyeloidleukemia[J].LeukemiaResearch,2012,36(7):803.

引证文献4

二级引证文献6

中国临床医学
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部